Dose, biotransformation and risk assessment
Toxicology relates an agent, dose, route, duration and host conditions to an effect. Hazard identifies the capacity to cause harm, whereas risk considers the exposure circumstances and probability or severity of that harm. A strongly hazardous substance may create little risk if exposure is effectively prevented, while a less potent agent can still cause substantial harm at sufficient exposure. These distinctions support control without implying that an unknown exposure is automatically acceptable.
Absorption, distribution, metabolism and elimination shape internal exposure. Phase I reactions can introduce or reveal functional groups, while phase II reactions can conjugate compounds with endogenous molecules. Biotransformation does not always detoxify: a reactive metabolite may be more harmful than the parent. The sequence is not mandatory for every compound, and a phase II pathway can act without a preceding phase I step.
Experimental endpoints must be interpreted within their study conditions. A median lethal dose summarizes a specified mortality endpoint and is not a safe dose, a treatment threshold or a complete chronic-risk assessment. A no-observed-adverse-effect level is bounded by the tested doses, sample and measured endpoints; it does not prove that no harm exists below it. A benchmark-dose approach asks a different model-based question using the response curve and its uncertainty.
Health-based guidance values can use a suitable point of departure and uncertainty factors. The factors depend on the evidence and intended assessment rather than always equaling one fixed number. Distinguish a supplied classroom calculation from the actual derivation for a specific chemical. A genotoxicity assay can indicate particular biological effects, but a positive screen alone does not establish the entire human cancer risk or identify a safe clinical action.
Acute poisoning requires prompt qualified care and prevention of further exposure. Recognizing a mechanism or naming an antidote does not supply the indication, timing, contraindications, supportive care or monitoring plan. Field personnel should not undertake unprotected rescue or improvise an antidote regimen from a multiple-choice answer. Document the agent, route, timing and available evidence, preserve relevant information safely and follow the appropriate emergency and public-health pathways.